U.S. markets closed
  • S&P Futures

    4,529.75
    -6.75 (-0.15%)
     
  • Dow Futures

    35,499.00
    -58.00 (-0.16%)
     
  • Nasdaq Futures

    15,324.00
    -17.00 (-0.11%)
     
  • Russell 2000 Futures

    2,284.10
    -4.70 (-0.21%)
     
  • Crude Oil

    84.02
    +0.26 (+0.31%)
     
  • Gold

    1,794.90
    -1.40 (-0.08%)
     
  • Silver

    24.47
    +0.02 (+0.09%)
     
  • EUR/USD

    1.1647
    +0.0016 (+0.14%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • Vix

    15.43
    +0.42 (+2.80%)
     
  • GBP/USD

    1.3763
    -0.0032 (-0.24%)
     
  • USD/JPY

    113.5460
    -0.4420 (-0.39%)
     
  • BTC-USD

    60,970.47
    -77.12 (-0.13%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.25 (+0.34%)
     

ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update and participate in one-on-one investor meetings at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Tuesday, March 9, 2021.

ObsEva webcast link [here]

The presentation and archived webcast will also be accessible under “Events Calendar” in the investors section of ObsEva’s [website].

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

For further information, please contact:

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617)-435-6602

###

Attachment